Senti Biosciences Reports Executive and Director Changes
Ticker: SNTI · Form: 8-K · Filed: Feb 6, 2025 · CIK: 1854270
Sentiment: neutral
Topics: management-change, board-composition, compensation
Related Tickers: SNTI
TL;DR
Senti Bio shake-up: new execs, directors, and pay plans effective Jan 31.
AI Summary
Senti Biosciences, Inc. filed an 8-K on February 6, 2025, reporting changes effective January 31, 2025. The filing details the departure of directors or certain officers, the election of new directors, the appointment of certain officers, and updates to compensatory arrangements for certain officers. Specific names and dollar amounts related to these changes are not detailed in the provided text.
Why It Matters
Changes in key leadership and compensation structures can signal shifts in company strategy, operational focus, or financial health.
Risk Assessment
Risk Level: medium — Changes in executive and director roles can indicate internal instability or strategic pivots, which carry inherent business risks.
Key Players & Entities
- Senti Biosciences, Inc. (company) — Registrant
- January 31, 2025 (date) — Effective date of reported changes
- February 6, 2025 (date) — Filing date of the 8-K
FAQ
Who are the specific directors or officers departing Senti Biosciences?
The provided text states that there were departures of directors or certain officers, but does not name the individuals involved.
Who has been elected as new directors for Senti Biosciences?
The filing indicates the election of directors, but the names of the newly elected directors are not specified in the provided excerpt.
Which officers have been appointed to new roles at Senti Biosciences?
The document mentions the appointment of certain officers, but does not list their names or specific positions.
What are the details of the compensatory arrangements for the officers mentioned?
The filing notes updates to compensatory arrangements for certain officers, but the specific terms and amounts are not detailed in the provided text.
What is the exact nature of the changes in leadership and compensation at Senti Biosciences?
The 8-K filing reports on the departure of directors/officers, election of directors, appointment of officers, and changes to compensatory arrangements, all effective January 31, 2025.
Filing Stats: 558 words · 2 min read · ~2 pages · Grade level 11.2 · Accepted 2025-02-06 17:30:11
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share SNTI The Nasdaq Capital Marke
Filing Documents
- snti-20250131.htm (8-K) — 27KB
- 0001628280-25-004293.txt ( ) — 151KB
- snti-20250131.xsd (EX-101.SCH) — 2KB
- snti-20250131_lab.xml (EX-101.LAB) — 22KB
- snti-20250131_pre.xml (EX-101.PRE) — 13KB
- snti-20250131_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SENTI BIOSCIENCES, INC. Date: February 06, 2025 By: /s/ Timothy Lu, M.D., Ph.D. Name: Timothy Lu, M.D., Ph.D. Title: Chief Executive Officer